Novo: This is where we will win and lose
At Novo Nordisk’s recent capital market day, a number of executives highlighted the company’s expectations for growth on emerging markets.
by Stefan Singh Kailay
There are especially two global pharma players trying to put pressure on the Danish diabetes giant, but, at the close of Q3 2013, Novo Nordisk still accounted for the lion’s share of the diabetes market that might be dubbed “the rest of the world”.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Here are the strategies of Novo’s rivals
For abonnenter
